ENRIGHT PATRICK G 4

What Happened
Patrick G. Enright, a director of BioAge Labs, Inc. (BIOA), was granted a derivative award covering 22,000 shares on June 10, 2026. The Form 4 reports the acquisition price as $0.00, indicating a grant/award (derivative) rather than an open-market purchase or sale. This was recorded as a grant/award (transaction code A); no exercise or sale occurred.

Key Details

• Transaction date: 2026-06-10 (reported on Form 4 filed 2026-06-12). Filing appears timely.
• Amount: 22,000 shares (reported as a derivative award) at $0.00 acquisition price.
• Shares owned after transaction: not disclosed in the provided filing.
• Footnote (F1): The entire option award vests on the earlier of (i) the date of the next annual meeting of stockholders or (ii) the one-year anniversary of the grant date, subject to continued service.
• Instrument: Reported as a derivative (option/award). Exercise price and full award terms are not detailed in the summary provided.

Context
This is a director compensation award (an option/derivative grant), not a purchase or sale. Such grants are common as part of board compensation and do not by themselves indicate insider buying or selling sentiment. The award vests on a short schedule (by next annual meeting or one year), and there was no immediate cash exercise or sale reported.